Oncology Gold Standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck

Abstract We present the 2017 Oncology Gold Standard Practical Consensus Recommendation for use of monoclonal antibodies in the management of advanced squamous cell carcinoma of head neck region.

[1]  H. Chaturvedi,et al.  Nimotuzumab with Concurrent Chemoradiation in Inoperable Locally Advanced Squamous Cell Carcinoma of Head and Neck: An Indian Experience , 2018 .

[2]  E. Sturgis,et al.  Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. , 2017, Practical radiation oncology.

[3]  Yahiya Y. Syed.  Durvalumab: First Global Approval , 2017, Drugs.

[4]  B. Devnani,et al.  Comparison between weekly cisplatin‐enhanced radiotherapy and cetuximab‐enhanced radiotherapy in locally advanced head and neck cancer: first retrospective study in Asian population , 2017, Asia-Pacific journal of clinical oncology.

[5]  Bingshu E. Chen,et al.  Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial , 2017, JAMA oncology.

[6]  S. Arya,et al.  A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers , 2017, South Asian Journal of Cancer.

[7]  S. Badhwar,et al.  Nimotuzumab and Intensity Modulated Radiation Therapy (IMRT) in the Concurrent Setting of Locally Advanced Head and Neck Cancers: Early Results of a Prospective Trial in India , 2016 .

[8]  D. Doval,et al.  Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study. , 2016, Indian journal of cancer.

[9]  R. Corvò,et al.  Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Huilgol.  A retrospective analysis of patients with head and neck cancer treated with radiation, hyperthermia, and cetuximab: A brief report of outcome. , 2016, Journal of cancer research and therapeutics.

[11]  K. Harrington,et al.  Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. , 2016 .

[12]  Chaosu Hu,et al.  Radiation plus concurrent nimotuzumab versus CDDP in locally advanced nasopharyngeal cancer: Results of a phase III randomised trial. , 2016 .

[13]  S. Goyal,et al.  Chemoradiation in elderly patients with head and neck cancers: a single institution experience. , 2015, American journal of otolaryngology.

[14]  Prevalence of Oral Cancer in India , 2015 .

[15]  Sue S Yom,et al.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. S. Kondaveeti,et al.  Therapeutic Benefit of Concurrent Radiation With Single Agent Nimotuzumab in Locally Advanced and Recurrent HNSCC: A Retrospective Analysis , 2014 .

[17]  A. Shenoy,et al.  Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. , 2014, Oral oncology.

[18]  Jun Wang,et al.  Challenges to effective cancer control in China, India, and Russia. , 2014, The Lancet. Oncology.

[19]  K. Ang,et al.  Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines. , 2013, Oral oncology.

[20]  S. Faivre,et al.  Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. , 2013, The Lancet. Oncology.

[21]  K. Bhowmik,et al.  Nimotuzumab with concurrent chemoradiotherapy in patients with locally advanced head and neck cancer (LASCCHN). , 2013 .

[22]  I. Floriani,et al.  Cetuximab/Radiation Therapy (CET + RT) Versus Concomitant Chemoradiation Therapy (cCHT + RT) With or Without Induction Docetaxel/Cisplatin/5Fluorouracil (TPF) in Locally Advanced Head-and-Neck Squamous Cell Carcinoma (LASCCHN) – Preliminary Results on Toxicity of a Randomized, 2x2 Factorial, Phase I , 2012 .

[23]  L. Crinò,et al.  Cetuximab/radiotherapy (CET+RT) versus concomitant chemoradiotherapy (cCHT+RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2x2 factorial, phase II-III study (N , 2012 .

[24]  K. Harrington,et al.  Zalutumumab in head and neck cancer , 2012, Expert opinion on biological therapy.

[25]  A. Chaturvedi,et al.  Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: a retrospective analysis. , 2012, Indian journal of cancer.

[26]  A. Munshi,et al.  Cetuximab and cancers of the head and neck: tapping the circadian rhythm. , 2011, Medical hypotheses.

[27]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  S. Basu,et al.  Retrospective analysis of head and neck cancer patients successfully treated with chemoradiation plus nimotuzumab. , 2011, Journal of Clinical Oncology.

[29]  I. Floriani,et al.  Concomitant chemoradiation or RT/cetuximab versus induction TPF followed by chemoradiation or RT/cetuximab in locally advanced head and neck squamous cell carcinoma: A randomized phase III factorial study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Gupta,et al.  Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice? , 2011, Indian journal of cancer.

[31]  C. Goswami,et al.  Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region--a open labelled single arm phase II study. , 2011, Indian journal of cancer.

[32]  R. Corvò,et al.  Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  R. Kerbel,et al.  Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile , 2011, Cancer biology & therapy.

[34]  V Grégoire,et al.  Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  M. Frómeta,et al.  Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck , 2010, Cancer biology & therapy.

[36]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[37]  F. Rivera,et al.  Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial , 2009, Expert review of anticancer therapy.

[38]  M. S. Ramakrishnan,et al.  Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin , 2009, mAbs.

[39]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[40]  Takeshi Ono,et al.  Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5‐fluorouracil and docetaxel in head and neck squamous cell carcinoma , 2006, Cancer science.

[41]  Suzanne L Wolden,et al.  Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Krause,et al.  Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.